about
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaEculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerationsComplement therapy in atypical haemolytic uraemic syndrome (aHUS).Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiencyComplement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Progress and Trends in Complement TherapeuticsRational engineering of a minimized immune inhibitor with unique triple-targeting properties.Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuriaPeptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Management of paroxysmal nocturnal haemoglobinuria: a personal view.Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis.Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test.
P2860
Q24193045-E9B876F8-BDAC-4BFB-ABAC-98E9F6C53729Q26740877-BA40F659-7049-4899-9777-7D685737C9E5Q33408733-B55C158A-D9DF-40AC-8572-100CD18CD13CQ34508358-8D3AD547-0E76-4AFF-A57F-620D6879AE21Q35252156-9516527D-031A-47AB-8F6A-F34F9BBE7B66Q36187306-63199C7D-50B5-4BF5-91AF-4E02948F6D0EQ36460034-ACC567B0-3366-452C-92CE-FC64F67F0ADAQ36479278-7CF86005-1144-41F5-B789-B1E1B7EF3546Q37300691-C998EE18-5339-4580-9AAA-C942EB609F92Q37552016-347330A3-DD3D-4797-A971-0E166A02B475Q37670073-EC249EC7-0EDB-4212-9A72-0B0A6C9A4DF1Q37724607-3424132C-8261-44BA-8F91-5F70E15BD402Q37868639-31701D69-847F-410B-A9E1-FBE907CE3320Q37956407-CB888470-2818-4408-90C7-7F63076BB29AQ39273772-16C7B2B1-4208-4C80-82CD-602343EFF746Q41091207-18DD3A18-3B6A-402D-A943-E1B8C491D390Q43441251-2A13CC36-39FB-4065-B0FA-C1051268473C
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@en
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@nl
type
label
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@en
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@nl
prefLabel
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@en
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@nl
P2860
P1433
P1476
Paroxysmal nocturnal hemoglobinuria and eculizumab.
@en
P2093
Antonio Maria Risitano
P2860
P304
P356
10.3324/HAEMATOL.2009.017848
P577
2010-04-01T00:00:00Z